You are here: Home Publications: Press Releases New Grades of Mirel Bioplastics

Metabolix Announces New Grades of Mirel Bioplastics for Injection Molding and Paper Coating

June 20, 2007

Cambridge, Massachusetts. Metabolix, Inc. (NASDAQ: MBLX) today announced that Telles, its joint venture with Archer Daniels Midland (NYSE: ADM) that produces Mirel bioplastics, has introduced three new grades of Mirel resins. The grades are Mirel P1001 and P1002 for injection molding applications and Mirel P2001 for paper coating. Mirel is a family of biobased, sustainable and biodegradable, semi-crystalline bioplastics.

For injection molding, Mirel P1001 is specifically engineered to replace styrenics such as polystyrene and Mirel P1002 replaces polyolefins such as polypropylene. "Mirel injection molding grades can be easily processed on conventional injection molding equipment", said Bob Findlen, VP of Sales and Marketing at Telles.

Mirel P2001 was developed as an alternative to petroleum-based paper coatings to enable the production of fully biodegradable paper coated cups and food packaging. “Mirel offers high heat resistance making it a superior biobased and biodegradable coating material for hot cups and microwaveable packages," said Findlen.

Mirel is a versatile brand of bioplastics produced from renewable resources like corn sugar that provides an excellent alternative to traditional, oil-based plastics. Unlike conventional plastics, Mirel will biodegrade harmlessly back to nature in a wide range of environments such as soil, compost, rivers, and oceans. For technical information, please visit www.telles-mirel.com.

About Metabolix
Founded in 1992, Metabolix, Inc. is an innovation driven bioscience company providing clean, sustainable solutions for the world's needs for plastics, fuels, and chemicals. The Company is taking a systems approach, from gene to end product, integrating sophisticated biotechnology with advanced industrial practice. Metabolix is now developing and commercializing Mirel bioplastics as the sustainable and totally biodegradable alternative to petroleum-based plastics. Metabolix is also developing a proprietary platform technology for co-producing bioplastics, biofuels and chemical products in biomass energy crops such as switchgrass. For more information, please visit www.metabolix.com. (MBLX-G)

About Telles
To commercialize Mirel bioplastics, Metabolix and ADM formed a joint venture which operates under the name Telles. Telles, which takes its name from the Roman goddess of the Earth, is responsible for the manufacturing, marketing and sales of Mirel worldwide. For more information, please visit www.telles-mirel.com.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding completion of construction on the commercial manufacturing facility, actual manufacturing capacity of the commercial manufacturing facility, manufacturing plans and performance including the timing of commencement of commercial production of Bioplastic, commercial viability of Bioplastic, sales potential of Bioplastic, timing of expansion of pre-commercial manufacturing capacity, timing of launch of branding for Bioplastics, current or future financial performance and position, management's strategy, plans and objectives for future operations, product development, present and future research and development, regulatory approval and intellectual property, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our dependence on our collaborative partner for construction of the commercial manufacturing facility, ADM's ability to complete construction of the commercial manufacturing facility on time and on budget, the ability of Metabolix and ADM to successfully manufacture Bioplastic at commercial scale and in a timely and economic manner, the success of collaborative arrangement with ADM, the ability to complete construction of the pre-commercial manufacturing facility expansion, the market acceptance of our products, our ability to compete with petrochemical-based plastics, fuels and chemicals, our ability to generate future revenues, our expectation of incurring continued losses, the success of our research and development programs, our ability to develop and successfully commercialize Bioplastic, our ability to obtain required regulatory approvals, our ability to obtain, maintain and protect intellectual property rights for our products, our limited sales and manufacturing capabilities, our ability to hire and retain skilled personnel, and other risks detailed in Metabolix' filings with the Securities and Exchange Commission, including form 10-K for the year ended December 31, 2006. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

View Full Press Release (PDF)

Contacts:

Media:
Brian Ruby
Integrated Corporate Relations
(203) 682-8268
brian.ruby@icrinc.com

OR

Matt Lindberg
Integrated Corporate Relations
(203) 682-8268
matthew.lindberg@icrinc.com

Investors:
Kathleen Heaney
Integrated Corporate Relations
(203) 803-3585
kheaney@icrinc.com